VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 404 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2016. The put-call ratio across all filers is 0.94 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $66,172,000 | +22255.4% | 2,846,096 | +13867.9% | 0.10% | +9900.0% |
Q4 2016 | $296,000 | -40.8% | 20,376 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $500,000 | +48.8% | 20,376 | +22.2% | 0.00% | 0.0% |
Q2 2016 | $336,000 | -17.6% | 16,671 | +7.6% | 0.00% | 0.0% |
Q1 2016 | $408,000 | -72.4% | 15,495 | +133.1% | 0.00% | -80.0% |
Q2 2015 | $1,477,000 | -97.1% | 6,648 | -97.4% | 0.01% | -96.9% |
Q1 2015 | $50,610,000 | +40.7% | 255,110 | +1.5% | 0.16% | +31.5% |
Q4 2014 | $35,962,000 | +99.1% | 251,272 | +82.4% | 0.12% | +79.7% |
Q3 2014 | $18,064,000 | +49.4% | 137,773 | +44.0% | 0.07% | +53.3% |
Q2 2014 | $12,089,000 | -53.4% | 95,655 | -51.5% | 0.04% | -52.1% |
Q1 2014 | $25,963,000 | -57.6% | 197,282 | -62.2% | 0.09% | -61.9% |
Q4 2013 | $61,253,000 | +55.1% | 521,971 | +37.8% | 0.25% | +30.7% |
Q3 2013 | $39,500,000 | +47.7% | 378,817 | +22.1% | 0.19% | +25.2% |
Q2 2013 | $26,743,000 | – | 310,214 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |